Cuvrior™(trientine tetrahydrochloride) – New orphan drug approval
April 28, 2022 - The FDA approved Orphalan’s Cuvrior (trientine tetrahydrochloride), for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
Download PDF
